open access

Vol 11, No 2 (2015)
Review paper
Published online: 2015-05-20
Get Citation

Subcutaneous trastuzumab — recent evidence on efficacy and safety in HER2-positive breast cancer patients

Katarzyna Pogoda, Anna Niwińska
Onkol. Prak. Klin 2015;11(2):93-99.

open access

Vol 11, No 2 (2015)
REVIEW ARTICLES
Published online: 2015-05-20

Abstract

Trastuzumab represented a breakthrough in the treatment of patients with HER2-positive breast cancer. Numerous clinical trials have shown its efficacy in patients with early, locally advanced and metastatic breast cancer. A more convenient formulation of subcutaneous (s.c.) trastuzumab has been developed. Based on the HannaH trial, which compared s.c. trastuzumab with the intravenous (i.v.) formulation, the European Medicines Agency has registered s.c. trastuzumab. The study showed that pathologic complete response and serum trough concentration at predose cycle 8, were non-interior to i.v. administration. Recently, the results of the HannaH study were presented with a median follow-up of 40 months. Event-free survival (no recurrence, progression or death due to any cause) rates at 3 years were similar in two arms (76% in trastuzumab s.c. and 73% in trastuzumab i.v. arm). In the PrefHer study most patients, as well as health-care professionals, preferred trastuzumab s.c. Injection-site reactions were mild and observed only in patients with trastuzumab s.c. Large SafeHer trial evaluating safety and tolerability of this drug formulation is ongoing. Preliminary results confirm the previous reports and safety of this therapy. Additionally, s.c. administration of trastuzumab reduces time of injection, patient time in care unit, risk of errors in drug dosage (fixed dose) and allows the performance of other duties within existing health-care resources.

Abstract

Trastuzumab represented a breakthrough in the treatment of patients with HER2-positive breast cancer. Numerous clinical trials have shown its efficacy in patients with early, locally advanced and metastatic breast cancer. A more convenient formulation of subcutaneous (s.c.) trastuzumab has been developed. Based on the HannaH trial, which compared s.c. trastuzumab with the intravenous (i.v.) formulation, the European Medicines Agency has registered s.c. trastuzumab. The study showed that pathologic complete response and serum trough concentration at predose cycle 8, were non-interior to i.v. administration. Recently, the results of the HannaH study were presented with a median follow-up of 40 months. Event-free survival (no recurrence, progression or death due to any cause) rates at 3 years were similar in two arms (76% in trastuzumab s.c. and 73% in trastuzumab i.v. arm). In the PrefHer study most patients, as well as health-care professionals, preferred trastuzumab s.c. Injection-site reactions were mild and observed only in patients with trastuzumab s.c. Large SafeHer trial evaluating safety and tolerability of this drug formulation is ongoing. Preliminary results confirm the previous reports and safety of this therapy. Additionally, s.c. administration of trastuzumab reduces time of injection, patient time in care unit, risk of errors in drug dosage (fixed dose) and allows the performance of other duties within existing health-care resources.

Get Citation

Keywords

safety, HER2, hyaluronidase, breast cancer, patient preference, subcutaneous injection

About this article
Title

Subcutaneous trastuzumab — recent evidence on efficacy and safety in HER2-positive breast cancer patients

Journal

Oncology in Clinical Practice

Issue

Vol 11, No 2 (2015)

Article type

Review paper

Pages

93-99

Published online

2015-05-20

Bibliographic record

Onkol. Prak. Klin 2015;11(2):93-99.

Keywords

safety
HER2
hyaluronidase
breast cancer
patient preference
subcutaneous injection

Authors

Katarzyna Pogoda
Anna Niwińska

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl